



Vol 7 No 5 Research article
Rheumatoid arthritis is an independent risk factor for multi-vessel 
coronary artery disease: a case control study
Kenneth J Warrington1,  P e t e rDK e n t 1, Robert L Frye2, James F Lymp4, Stephen L Kopecky2,3, 
Jörg J Goronzy1,5 and Cornelia M Weyand1,5
1Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
2Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
3Mayo Alliance for Clinical Trials and the Mayo Clinic, Rochester, MN, USA
4Division of Biostatistics, Mayo Clinic, Rochester, MN, USA
5Emory University School of Medicine, Atlanta, GA, USA
Corresponding author: Kenneth J Warrington, kwarring@utmem.edu
Received: 29 Dec 2004 Revisions requested: 27 Jan 2005 Revisions received: 23 May 2005 Accepted: 25 May 2005 Published: 29 Jun 2005
Arthritis Research & Therapy 2005, 7:R984-R991 (DOI 10.1186/ar1775)
This article is online at: http://arthritis-research.com/content/7/5/R984
© 2005 Warrington et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The risk for cardiovascular (CV) disease is increased in
rheumatoid arthritis (RA) but data on the burden of coronary
atherosclerosis in patients with RA are lacking. We conducted
a retrospective case-control study of Olmsted County (MN,
USA) residents with RA and new-onset coronary artery disease
(CAD) (n  = 75) in comparison with age-and sex-matched
controls with newly diagnosed CAD (n = 128). Angiographic
scores of the first coronary angiogram and data on CV risk
factors and CV events on follow-up were obtained by chart
abstraction. Patients with RA were more likely to have multi-
vessel coronary involvement at first coronary angiogram
compared with controls (P  = 0.002). Risk factors for CAD
including diabetes, hypertension, hyperlipidemia, and smoking
history were not significantly different in the two cohorts. RA
remained a significant risk factor for multi-vessel disease after
adjustment for age, sex and history of hyperlipidemia. The overall
rate of CV events was similar in RA patients and controls;
however, there was a trend for increased CV death in patients
with RA. In a nested cohort of patients with RA and CAD (n =
27), we measured levels of pro-inflammatory CD4+CD28null T
cells by flow cytometry. These T cells have been previously
implicated in the pathogenesis of CAD and RA. Indeed,
CD4+CD28null T cells were significantly higher in patients with
CAD and co-existent RA than in controls with stable angina (P
= 0.001) and reached levels found in patients with acute
coronary syndromes. Patients with RA are at increased risk for
multi-vessel CAD, although the risk of CV events was not
increased in our study population. Expansion of CD4+CD28null
T cells in these patients may contribute to the progression of
atherosclerosis.
Introduction
Inflammation plays a central role in the pathogenesis of athero-
sclerosis [1,2]. Markers of inflammation, such as C-reactive
protein, are predictive of future cardiovascular (CV) events in
healthy individuals and may be useful in identifying patients
with coronary artery disease (CAD) who are at risk for recur-
rent CV events [3,4]. Atherosclerotic plaque is a complex
inflammatory lesion characterized by an infiltrate of macro-
phages and T cells [1]. Intraplaque immune cells are activated
and involved in mediating tissue injury [5]. T-cell cytokines can
drive macrophage activation in atherosclerotic lesions and can
also regulate the acute-phase response [1]. Indeed, T cells in
patients with acute coronary syndromes (ACS) are skewed
toward the production of interferon (IFN)-γ , a potent monocyte
activator largely derived from a distinct subset of CD4+ T cells
[6,7] that, in contrast to classic CD4+ helper T cells, lacks the
costimulatory molecule CD28 [8]. CD4+CD28null T cells are
clonally expanded in ACS and invade the unstable atheroscle-
rotic plaque [9]. Moreover, CD4+CD28null T cells have cyto-
toxic capability, can effectively kill endothelial cells in vitro, and
may contribute to endothelial cell injury in coronary plaque
[10].
ACS = acute coronary syndrome; CABG = coronary artery bypass graft; CAD = coronary artery disease; CV = cardiovascular; HR, hazard ratio; 
DMARD = disease-modifying antirheumatic drugs; MI = myocardial infarction; OR = odds ratio; PTCR = percutaneous transluminal coronary revas-
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Expansion of CD4+CD28null T cells was initially described in
patients with rheumatoid arthritis (RA), a chronic autoimmune
disease of unknown etiology [11]. RA is characterized by
chronic inflammation and hyperplasia of synovial tissue. More
importantly, it is a quintessential systemic disease that can
manifest in most major organ systems [12]. T cells play a cen-
tral role in the immunopathogenesis of RA and are the key reg-
ulators of the chronic destructive joint lesions [13]. In addition,
patients with RA have abnormalities in T-cell homeostasis that
affect the entire pool of T cells [14,15]. One of the conse-
quences of dysregulated T-cell homeostasis is the emergence
of large clonal CD4+CD28null T-cell populations that are auto-
reactive and cytotoxic, and infiltrate synovial tissue [15]. The
highest frequency of CD4+CD28null T cells is found in severe
RA, particularly in patients with rheumatoid vasculitis [11,16].
When the inflammatory process in RA spreads to extra-articu-
lar sites, such as mid-size arteries and capillaries, morbidity
and mortality are clearly increased [17].
Because the chronic inflammatory process and immune dys-
regulation in RA have features in common with those involved
in atherosclerosis, they could predispose patients with RA to
accelerated CAD. Several studies have documented an
increased risk of atherosclerosis and myocardial infarction in
patients with RA [18-20]. In addition, RA is associated with a
reduced life expectancy, primarily because of excessive
deaths from CV disease [21-25]. RA is a heterogeneous dis-
ease, and the disease phenotype itself is predictive of mortal-
ity; patients with more severe clinical disease have higher
mortality rates [26]. Overall mortality is also increased in
patients who are positive for the autoantibodies, rheumatoid
factors [27,28]. In addition, the extent of inflammation in RA
has been linked to an increased risk of CV mortality [29]. The
number of swollen joints, independent of traditional CV risk
factors, is predictive of CV-related deaths among Pima Indians
with RA [30]. The strongest association with increased CV
mortality is seen in patients with extra-articular manifestations
of RA [17].
Our study demonstrates that patients with RA have signifi-
cantly more multi-vessel coronary disease by angiography
compared with patients with CAD but no RA. This finding may,
at least in part, result from the expansion of proinflammatory
CD4+CD28null T cells that have previously been shown to play
a role in the pathogenesis of CAD.
Methods
Data source
The Rochester Epidemiology Project maintains the medical
records of patients from Mayo Clinic Rochester, MN, USA,
which is the major referral center for secondary and tertiary
care, including coronary angiography, in Olmsted and sur-
rounding counties. The complete medical records of each
study subject were retrieved and reviewed. The study was
approved by the Mayo Foundation Institutional Review Board
and patient consent was obtained.
Patient population
We studied the medical records of patients from Olmsted and
surrounding counties. Patients with RA who developed CAD
between January 1985 and December 1998 and who had a
coronary angiogram at Mayo Clinic Rochester were recruited
for the study. Inclusion criteria were: diagnosis of RA accord-
ing to the 1987 American College of Rheumatology criteria
[31]; diagnosis of ischemic heart disease (ischemic heart dis-
ease criteria were anginal pain or anginal equivalent symptoms
occurring with exercise, relief by rest or nitroglycerin. If occur-
ring at rest, then symptoms relieved with nitroglycerin); and
coronary angiography performed at Mayo Clinic for evaluation
of CAD within the first 12 months of disease. Mayo Clinic is
the only provider of invasive cardiac care in Olmsted County.
Exclusion criteria were: congestive heart failure without
ischemic heart disease; CAD present for more than 12 months
prior to the first angiogram at Mayo Clinic (to ensure that all
angiograms reflected the status of the patient at onset of CAD
symptoms); and prior coronary artery bypass graft (CABG),
myocardial infarction (MI) or percutaneous transluminal coro-
nary revascularization (PTCR). Death during the study period
1985 to 1998 was not an exclusion criterion.
Residents of Olmsted and surrounding counties who were
seen at Mayo Clinic between January 1985 and December
1998 and diagnosed with CAD during the study period were
used as control subjects. The original study design was to
match three controls for each of the 75 RA cases for age, sex
and visit date. Controls were matched for age at diagnosis of
CAD and year of onset in order to control for shifts in practice
and diagnostic patterns. Using these criteria, we were able to
identify 130 controls, therefore some cases had one control
and others had two controls. After matching, two patients
were excluded for prior CABG, MI, PTCR or no angiogram at
Mayo Clinic, resulting in 128 controls. Inclusion/exclusion cri-
teria were identical except that a diagnosis of RA was an addi-
tional exclusion criterion. The controls were from the local,
stable population of Olmsted and surrounding counties. The
only rheumatology practice in this geographic area is at Mayo
Clinic. The investigators reviewed the entire Mayo medical
record (including the master sheet listing all diagnoses for the
patient throughout his/her lifetime) for each control. We are
confident that symptoms or clinical manifestations of RA
would have been recorded in the patients' charts. The diagno-
sis for RA was based on a rheumatologist's evaluation.
Coronary angiogram data
Angiographic data was retrieved from the Mayo Clinic coro-
nary care unit database. Mayo Clinic cardiologists who per-
formed the study and read each angiogram were not directly
involved in each patient's medical care and, therefore, notAvailable online http://arthritis-research.com/content/7/5/R984
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typically informed of the patient's concurrent medical prob-
lems. Vessel involvement was defined as >50% stenosis for
the left main coronary artery and >70% stenosis for the left
anterior descending, right coronary and circumflex arteries.
For each involved vessel, the patient received a score of 1.
Ischemic risk factors
Ischemic heart disease risk factors were ascertained by medi-
cal record review and were defined as follows: cholesterol
ever ≥  200 mg/dl and/or treated by a physician for hypercho-
lesterolemia, hypertension under treatment, smoking history
(yes or no), and type I or type II diabetes. We have selected
variables in our analysis where the data sets were largely com-
plete and where there was not a difference between the two
patient cohorts in terms of missing data. Variables for which
we did not have a complete dataset (such as quantitative
details of smoking history) were excluded.
Immune markers
In a nested study, all RA+CAD subjects who were alive at the
time of the study were contacted by mail and invited to partic-
ipate in the immune marker analysis. Of these, 27 individuals
consented to blood donation, and peripheral blood was
obtained for T-cell phenotyping (n = 27). This patient sub-
group had similar demographic characteristics as the whole
RA+CAD cohort. Mean age for the subgroup was 69.2 ± 8.2
years, 58% were male and 87% were rheumatoid factor-posi-
tive. RA disease duration was also similar (15.9 ± 9.9 years).
Blood samples were also obtained from controls who were
classified as having had stable angina (n = 24). Results were
compared with 22 patients with unstable angina type Braun-
wald IIIb, from a previous study [6].
Peripheral blood mononuclear cells were isolated by density
gradient centrifugation with Ficoll-Paque (Amersham Bio-
sciences, Arlington Heights, IL, USA). Cell surface staining
was performed using anti-CD4FITC and anti-CD28PE antibod-
ies (BD Biosciences, San Jose, CA, USA). Data was collected
on a FACScan flow cytometer (Becton Dickinson, San Jose,
CA, USA), and the frequencies of CD4+ T-cell subsets were
calculated using WinMDI software (Joseph Trotter, Scripps
Research Institute, La Jolla, CA, USA).
Statistical methods
All time references are based on the index angiogram. For
each patient, the following variables were considered: RA
diagnosis; number of diseased vessels (0, 1, 2 or 3); age and
sex; history of diabetes, hypertension, hyperlipidemia or smok-
ing; time to death, follow-up angiogram, follow-up CABG or
follow-up MI; and time to first event [death, CV death, angi-
ogram, CABG or MI]. In all models, the number of diseased
vessels was treated as a four-level categorical variable.
The first component of the analyses was the exploration of
baseline factors associated with RA diagnosis and number of
diseased vessels. These data were cross-tabulated with each
other and with each of the other baseline variables. Chi-square
tests or Wilcoxon rank-sum tests were performed as appropri-
ate. A multiple logistic regression model, with RA diagnosis as
the dependent variable, was constructed using forward selec-
tion, with smallest P < 0.05 as the entry criterion. Additionally,
a multiple ordinal logistic regression model, with number of
diseased vessels as the dependent variable, was constructed
using forward selection, with smallest P < 0.05 as the entry
criterion.
The second component of the analyses was the exploration of
follow-up events. RA diagnosis was cross-tabulated with the
various follow-up events: time to death, CV death, time to fol-
low-up angiogram, follow-up CABG, follow-up MI and first
event (death, angiogram, CABG or MI). The cases and con-
trols were defined during a specified time interval and each
subject was followed for subsequent events. Therefore, the
study group is a sample from a cohort of patients with CAD,
some with RA and some without RA, allowing us to use Cox
proportional hazards models for each of the five follow-up end-
points and for RA diagnosis. Adjusted Cox proportional haz-
ards models were fit by adding the number of diseased
vessels and hyperlipidemia as covariates. For time to death, a
Cox model was fit for each of the other baseline variables.
Kaplan-Meier survival plots were constructed for time to death
as a function of each baseline variable. Statistical analyses
were performed using SAS Release 8.2 (TS2M0) for UNIX
(SAS Institute Inc, Cary, NC, USA) and S-PLUS 2000 Profes-
sional Release 2 for Windows (Insightful Corp, Seattle, WA,
USA). CD4+CD28null  T-cell percentages were compared
using the Mann-Whitney rank sum test.
Results
Demographic characteristics and CAD risk factors
The study population consisted of 79 patients with RA who
had coronary angiography performed at Mayo Clinic for CAD
symptoms. Four were excluded because of history of CAD
diagnosis and intervention prior to evaluation at Mayo. The
control population consisted of 130 individuals with CAD but
no history of RA, two of whom were excluded because of a his-
tory of prior CV events. The analyzed dataset consisted of 75
cases and 128 controls.
There was no significant difference in the percentage of indi-
viduals with traditional risk factors for CAD, including diabetes,
hypertension, hyperlipidemia or smoking history in the study
group when compared with controls (Table 1). Because age
and sex were incorporated in the matching, there was no dif-
ference between the two groups.
Characteristics of cases with RA and CAD
Table 1 includes characteristics of the patients with RA. Aver-
age age at onset of RA was 55 years and the average diseaseArthritis Research & Therapy    Vol 7 No 5    Warrington et al.
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duration was 17.6 years. Approximately 90% of the cases
were rheumatoid factor-positive and 53% had nodular dis-
ease. One-fifth of the group had extra-articular disease mani-
festations including vasculitis, rheumatoid lung disease,
pericarditis, Felty's syndrome, neuropathy and scleritis. Use of
corticosteroids and disease modifying therapy was fairly typi-
cal of patients with long-standing RA.
Coronary artery involvement
There was a statistically significant difference in the distribu-
tion of the number of involved vessels in the two groups. More
patients with RA had significant coronary artery involvement
compared with controls (P = 0.002, chi-square = 14.6866, df
= 3; Table 2). Only 4% of the patients with RA had no signifi-
cant vessel involvement compared with 23% for the control
patients.
RA is an independent risk factor for increased CAD 
severity
Table 3 shows the ordinal logistic regression model results for
number of diseased vessels. One model includes only RA
diagnosis and the other also includes the covariates added via
the forward selection procedure. These variables were added
because they were related to the number of diseased vessels.
RA remains a significant risk factor for multi-vessel disease
after adjustment for age, sex, and history of hyperlipidemia.
The odds ratio of RA diagnosis for an increase of one diseased
vessel is 1.73 (95% CI: 1.03, 2.91) unadjusted and 1.97
(95% CI: 1.15, 3.36) adjusted.
Table 1
Patient demographics
Variable RA + CAD (n = 75) CAD (n = 128) Pa
Age, median (Q1, Q3) 66.4 (60.7, 71.7) 66.7 (59.8, 71.4) 0.66
Sex, n (%) 0.63
Male 39 (52) 71 (55) -
Female 36 (48) 57 (45) -
History of diabetes, n (%) 14 (19) 24 (19) 0.99
History of hypertension, n (%) 28 (37) 51 (40) 0.72
History of hyperlipidemia, n (%) 11 (15) 31 (24) 0.10
History of smoking, n (%) 11 (15) 23 (18) 0.54
Age at RA onset, year 55.3 ± 12.7 -
RA disease duration, year 17.6 ± 11.0 -
Rheumatoid factor positive, n (%) 68 (90.7) -
Nodular disease, n (%) 40 (53.3) -
Extra-articular disease, n (%) 16 (21.3) -
Steroid use, n (%) 55 (73.3) -
DMARD use, n (%) 68 (90.7) -
aP values are from chi-square tests, except for age, where it is from a Wilcoxon rank-sum test. CAD, coronary artery disease; DMARD, disease-
modifying antirheumatic drug; RA, rheumatoid arthritis.
Table 2
Angiography results
RA + CAD (n = 75) CAD (n = 128)
Number of diseased vessels, n (%)
0 3 (4) 30 (23)
1 36 (48) 43 (34)
2 18 (24) 33 (26)
3 18 (24) 22 (17)
CAD, coronary artery disease; RA, rheumatoid arthritisAvailable online http://arthritis-research.com/content/7/5/R984
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CV events
Because RA was associated with more severe coronary dis-
ease, we investigated whether this resulted in an increased
incidence of CV events and/or premature mortality. Follow-up
data for CV events including CV death, death from any cause,
CABG, MI and PTCR was recorded by review of the medical
record. Mean duration of follow-up was 62.4 months for the
RA and CAD cases and 57.8 months for the CAD-only con-
trols. The mean time from CAD onset to occurrence of a CV
event (MI, CABG or PTCR) was 18 months and the mean time
to death from any cause was 63 months. The risk of non-fatal
CV events did not differ significantly between cases and con-
trols. However, RA and CAD cases tended to have increased
all-cause mortality (32%) compared with CAD only controls
(18%); unadjusted risk ratio = 1.6 (95% CI: 0.9–2.9). In par-
ticular, the risk of CV death was increased in RA and CAD
cases (17%) compared with CAD-only controls (7%); unad-
justed hazard ratio (HR)=2.2 (95% CI: 0.95–5.2). However,
neither comparison reached significance.
Table 4 shows raw counts and Cox model results for various
follow-up endpoints. Of the 203 patients in the study, 47 died,
52 had follow-up CABG events, 71 had follow-up MI, 74 had
follow-up PTCR and 141 had 'any event'. RA is weakly associ-
ated with an increased risk of all-cause mortality, adjusted risk
ratio = 1.3 (95% CI: 0.7–2.3). There is a stronger association
between RA and an increased risk of CV death, adjusted HR
= 1.9 (95% CI: 0.8–4.7); however, this is not significant. There
is no apparent association between case/control status and
the percentage of individuals who had non-fatal CV events
during the follow-up period.
As expected, other factors were associated with increased
mortality. Based on bivariate Cox proportional hazards models
including all subjects, the presence of involved vessels is
associated with an increase in risk of death (risk ratio = 2.9,
3.0 and 4.6 for 1, 2 and 3 vessels, respectively; P = 0.06).
Also, history of diabetes (risk ratio = 1.9; P = 0.05) and age is
associated with an increase in risk of death (risk ratio per 1
year age increase = 1.07; P < 0.001).
Survival plots
Figure 1a shows Kaplan-Meier plots of survival by case/control
status. Survival probability for patients with RA and CAD was
lower than that for patients with CAD only (P = 0.10). Figure
1b shows Kaplan-Meier plots of survival by number of dis-
eased vessels. Survival probability was lowest for patients with
three diseased vessels and was progressively higher as the
number of diseased vessels decreased (P = 0.06).
Table 3
Ordinal logistic regression models for the number of diseased vessels
Variable Unadjusted OR (95% CI) P Adjusted ORa(95% CI) P
RA diagnosis 1.73 (1.03, 2.91) 0.04 1.97 (1.15, 3.36) 0.01
History of hyperlipidemia NA NA 2.56 (1.35, 4.85) 0.004
Age (per year increase) NA NA 1.05 (1.02, 1.07) 0.002
Sex (female relative to male) NA NA 0.40 (0.23, 0.67) 0.001
aAdjusted model is the result of a forward selection procedure, and adjustment was made for age, sex and history of hyperlipidemia.
CI, confidence interval; NA, not applicable; OR, odds ratio; RA, rheumatoid arthritis.
Table 4
Summary of events during follow-upa
Event RA + CAD (n = 75), n (%) CAD (n = 128), n (%) Unadjusted HR (95% CI) P Adjusted HRb (95% CI) P
CV death 13 (17) 9 (7) 2.22 (0.95, 5.20) 0.06 1.94 (0.80, 4.69) 0.14
Death 24 (32) 23 (18) 1.63 (0.92, 2.89) 0.10 1.29 (0.72, 2.32) 0.39
CABG during follow-up 18 (24) 34 (27) 0.87 (0.49, 1.53) 0.62 0.80 (0.44, 1.44) 0.45
MI during follow-up 28 (37) 43 (34) 1.08 (0.67, 1.73) 0.77 0.79 (0.48, 1.28) 0.34
PTCR during follow-up 27 (36) 47 (37) 0.78 (0.43, 1.41) 0.41 0.69 (0.37, 1.27) 0.23
Any event 53 (71) 88 (69) 1.19 (0.84, 1.68) 0.34 1.05 (0.73, 1.50) 0.81
aRaw counts and Cox model results for various follow-up endpoints.
bAdjusted models include number of vessels and hyperlipidemia in the model as covariates.
CABG, coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial 
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CD4+CD28null T cells
As previously reported, frequencies of CD4+CD28null T cells
were low in individuals with stable angina (median: 0.7%) [6].
In contrast, individuals with unstable coronary syndromes
(without RA) had an almost sevenfold expansion of
CD4+CD28null T cells (median: 4.8%, P = 0.009 for stable vs
unstable angina comparison). A similar expansion of
CD4+CD28null T cells was found in patients with RA and CAD
(median: 3.5%; 25th percentile: 0.9%; 75th percentile:
12.4%). Frequencies of proinflammatory CD4+CD28null T cells
were not significantly different between patients with unstable
angina (without RA) and those with RA and CAD. Although the
patients with RA did not have symptoms of acute plaque insta-
bility at the time of the immunological test, the majority of them
(81.5%) had a history of unstable angina. The difference
between the patients with RA and CAD and stable angina con-
trols was highly significant (P = 0.001) (Figure 2).
Discussion
Our results show that patients with RA have more advanced
coronary atherosclerosis at the time of CAD diagnosis com-
pared with patients without RA (Table 2). This occurs
independently of the traditional CV disease risk factors. More
importantly, this results in a trend towards increased frequency
of CV death for patients with RA.
In the general population, the presence of advanced athero-
sclerosis on angiography is predictive of a worse prognosis
[32]. The extent of atherosclerosis determined by angiography
has not been studied in RA. Indirect evidence of accelerated
atherosclerosis in RA comes from studies using carotid artery
intima medial thickness as a marker of atherosclerotic burden
and vascular risk [19,33,34]. Increased intima-media thick-
ness was independent of traditional CV risk factors but was
related to RA disease activity [20], duration and severity [19].
Data presented here suggest that the acceleration of
atherosclerotic disease in RA holds for multiple vascular beds,
lending support to a systemic disease mechanism.
Excess CV morbidity in RA
Patients with RA have a significantly higher prevalence of
angina pectoris [34]. Also, women with RA have a significantly
increased risk of myocardial infarction compared with those
Figure 1
Kaplan-Meier survival curves in CAD patients Kaplan-Meier survival curves in CAD patients. Curves include all sub-
jects with CAD classified according to pre-existent RA and to the 
number of diseased coronary vessels. (a) Survival probability was lower 
in patients with RA (P = 0.097) and (b) in patients with three affected 
vessels (P = 0.059).
Figure 2
Expansion of non-classic CD4+CD28null T cells in patients with RA and  CAD Expansion of non-classic CD4+CD28null T cells in patients with RA and 
CAD. Frequencies of CD4+CD28null T cells were determined by flow 
cytometry. Data are presented as box plots with medians, 25th and 
75th percentiles as boxes and 10th and 90th percentile as whiskers. 
CD4+CD28null T cells are infrequent in donors with stable angina and 
are significantly expanded in patients with unstable angina (P = 0.009). 
Patients with RA and CAD resemble patients with plaque instability and 
differ from those with stable angina (P = 0.001).Available online http://arthritis-research.com/content/7/5/R984
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without RA [18]. This excess of CV disease in RA cannot be
explained by the traditional Framingham risk factors [35] and
probably arises from the underlying disease and/or its treat-
ment. There is no evidence that disease-modifying antirheu-
matic drug (DMARD) therapy increases mortality in RA [36].
Corticosteroids can cause dyslipidemia, hyperglycemia and
hypertension but may also control inflammation in RA. Studies
have attempted to define the impact of steroids on mortality in
RA but the results are inconsistent [23,25]. DMARD treatment
can actually improve the outcome in RA. Choi and colleagues
[36] have demonstrated that methotrexate-treated patients
had a 70% reduction in CV deaths compared with those who
did not receive disease-modifying therapy. Other DMARDs
such as sulfasalazine, penicillamine, hydroxychloroquine, and
gold did not confer this protection. Thus, the RA disease proc-
ess itself likely contributes to accelerated CAD.
The inflammatory mechanisms in RA may enhance atherogen-
esis in several ways. C-reactive protein, a useful marker of dis-
ease activity, is elevated in RA and has prognostic value [37].
It may also participate directly in endothelial injury by sensitiz-
ing endothelial cells to T-cell mediated cytotoxicity [10]. Circu-
lating cytokines in RA, such as TNF-α , result in endothelial
activation and up-regulation of adhesion molecules [38].
Indeed, endothelial dysfunction is frequently present in RA
patients, even in the absence of identifiable CV risk factors
[39] and improves with anti-TNF-α  therapy [40]. Cytokines will
also non-specifically activate monocytes and other cells of the
innate immune system. RA is characterized by the expansion
of autoreactive T-cell clones that typically lack CD28 [11]. The
frequency of such CD4+CD28null T cells correlates with dis-
ease severity with respect to erosive progression [41] and
extra-articular manifestations. The frequency in the RA with
CAD cohort (median 3.5%) was higher than in historical con-
trols of patients with RA and absence of extra-articular mani-
festations [11], suggesting that CV comorbidity in RA is
correlated with disease severity and that CD4+CD28null T cells
may be involved in the CV complications of RA. CD4+CD28null
T cells have been directly implicated in the pathogenesis of
coronary artery disease [6]. Persistent activation of such auto-
reactive cells in RA may result in a vicious cycle of cytokine
release, mononuclear cell activation and tissue injury. How-
ever, we cannot exclude the possibility that the high
CD4+CD28null T cells levels in RA with CAD patients is reflec-
tive of an increased RA disease severity in these patients.
Addressing this issue further will require comparing RA
patients that are matched for disease severity but are dispa-
rate for CAD.
Study limitations
We adjusted for traditional Framingham risk factors that are
commonly considered in epidemiological studies of CV dis-
ease. However, factors such as cigarette smoking could pos-
sibly have a synergistic effect with chronic inflammation due to
RA, resulting in increased atherogenesis. In our study, detailed
quantitative data on amounts of tobacco used were not avail-
able. Also, data regarding other risk factors, such as family his-
tory and body mass index, were not available. Elevated levels
of homocysteine could represent another risk factor for athero-
sclerosis in RA. Methotrexate, a commonly used disease-mod-
ifying agent, inhibits dihydrofolate reductase and reduces
levels of folate, which in turn increases levels of homocysteine
[42,43]. The impact of folic acid supplementation on homo-
cysteine levels and CV disease in patients with RA is
unknown. Data on homocysteine levels were not available in
our study. Finally, it is possible that our findings are a reflection
of patients with RA being less symptomatic from CAD than the
general population, therefore resulting in later presentation
when the disease is more advanced.
Despite more severe CAD at the time of clinical presentation,
the prevalence of non-fatal CV events was not increased in
patients with RA. It is possible that significant differences
between cases and controls were not detected because of the
size of the cohorts studied and also that CV events may have
been underestimated due to the retrospective nature of the
study.
Conclusion
In summary, our results demonstrate that patients with RA
have a greater burden of coronary atherosclerosis at their first
angiogram that is independent of traditional CV risk factors.
This may be due, at least in part, to the expansion of nonclassic
CD4+ T cells that have previously been implicated in the
pathogenesis of CAD [6,9].
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